HDL particle number measured on the Vantera®, the first clinical NMR analyzer

Clinical Biochemistry

Volumn 48, Issue 3, 2015, Pages 148-155

  Matyus, Steven P ^a   Braun, Paul J ^a   Wolak Dinsmore, Justyna ^a   Saenger, Amy K ^b   Jeyarajah, Elias J ^a   Shalaurova, Irina ^a   Warner, Suzette M ^a   Fischer, Timothy J ^a   Connelly, Margery A ^a  

^a LIPOSCIENCE INC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Cardiovascular disease; High density lipoprotein; Lipoprotein particle analysis; NMR spectroscopy

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN PARTICLE; NICOTINIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYZER; ARTICLE; BIOASSAY; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HIGH DENSITY LIPOPROTEIN PARTICLE ASSAY; HUMAN; INTERMETHOD COMPARISON; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFERENCE VALUE; ADOLESCENT; BLOOD; DEVICES; LABORATORY DIAGNOSIS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES; REPRODUCIBILITY; STANDARD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL, HDL; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PARTICLE SIZE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; YOUNG ADULT;

EID: 84921803832     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.11.017     Document Type: Article

References (38)

1. Barr D.P., Russ E.M., Eder H.A. Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. Am J Med 1951, 11:480-493.
2. Castelli W.P. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996, 124:S1-S9. (Suppl.).
3. Emerging Risk Factors C, Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., Ray K.K., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000.
4. Emerging Risk Factors C, Di Angelantonio E., Gao P., Pennells L., Kaptoge S., Caslake M., et al. Lipid-related markers and cardiovascular disease prediction. JAMA 2012, 307:2499-2506.
5. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004, 44:720-732.
6. Tuteja S., Rader D.J. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm. Clin Pharmacol Ther 2014, 96(1):48-56.
7. Kingwell B.A., Chapman M.J., Kontush A., Miller N.E. HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov 2014, 13(6):445-464.
8. Vickers K.C., Remaley A.T., Vickers K.C. Functional diversity of HDL cargo. J Lipid Res 2013, 55:4-12.
9. Vaisar T., Pennathur S., Green P.S., Gharib S.A., Hoofnagle A.N., Cheung M.C., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007, 117:746-756.
10. Shah A.S., Tan L., Long J.L., Davidson W.S. Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J Lipid Res 2013, 54:2575-2585.
11. Camont L., Chapman M.J., Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 2011, 17:594-603.
12. Rosenson R.S., Brewer H.B., Ansell B., Barter P., Chapman M.J., Heinecke J.W., et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation 2013, 128:1256-1267.
13. HB G., Rao V.S., Kakkar V.V. Friend turns foe: transformation of anti-inflammatory HDL to proinflammatory HDL during acute-phase response. Cholesterol 2011, 2011:274629.
14. Mackey R.H., Greenland P., Goff D.C., Lloyd-Jones D., Sibley C.T., Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2012, 60:508-516.
15. Parish S., Offer A., Clarke R., Hopewell J.C., Hill M.R., Otvos J.D., et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 2012, 125:2469-2478.
16. Mora S., Glynn R.J., Ridker P.M. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 2013, 128:1189-1197.
17. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006, 26:847-870.
18. Otvos J.D., Jeyarajah E.J., Bennett D.W. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin Chem 1991, 37:377-386.
19. Otvos J.D., Jeyarajah E.J., Bennett D.W., Krauss R.M. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992, 38:1632-1638.
20. Matyus S.P., Braun P.J., Wolak-Dinsmore J., Jeyarajah E.J., Shalaurova I., Xu Y. NMR measurement of LDL particle number using the Vantera Clinical Analyzer. Clin Biochem 2014, 47(16):203-210.
21. Smallcombe S.H.P.S., Keifer P.A. Wet solvent suppression and its applications to LC NMR and high-resolution NMR spectroscopy. J Magn Reson 1995, A117:295-303.
22. CLSI Document EP17-A: Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline 2004, Clinical and Laboratory Standards Institute, Wayne, PA USA.
23. CLSI Document EP5-A2: Evaluation of Precision Performance of Quantitative Measurements Methods; Approved Guideline-Second Edition 2004, Clinical and Laboratory Standards Institute, Wayne, PA.
24. CLSI document EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach 2003, Clinical and Laboratory Standards Institute, Wayne, PA.
25. Schumaker V.N., Puppione D.L. Sequential flotation ultracentrifugation. Methods Enzymol 1986, 128:155-170.
26. Otvos J.D., Jeyarajah E.J., Hayes L.W., Freedman D.S., Janjan N.A., Anderson T. Relationships between the proton nuclear magnetic resonance properties of plasma lipoproteins and cancer. Clin Chem 1991, 37:369-376.
27. CLSI document EP9-A2: Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline-Second Edition 2002, Clinical and Laboratory Standards Institute, Wayne, PA.
28. CLSI Document C28-A3: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline-Third Edition 2008, Clinical and Laboratory Standards Institute, Wayne, PA.
29. CLSI document EP7-A2: Interference testing in clinical chemistry; approved guideline-second edition 2007, Clinical and Laboratory Standards Institute, Wayne, PA.
30. Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults. JAMA 2001, 285:2486-2497.
31. Rosenson R.S., Brewer H.B., Davidson W.S., Fayad Z.A., Fuster V., Goldstein J., et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012, 125:1905-1919.
32. Barylski M., Toth P.P., Nikolic D., Banach M., Rizzo M., Montalto G. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract Res Clin Endocrinol Metab 2014, 28:453-461.
33. Caulfield M.P., Li S., Lee G., Blanche P.J., Salameh W.A., Benner W.H., et al. Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin Chem 2008, 54:1307-1316.
34. Hutchins P.M., Ronsein G.E., Monette J.S., Pamir N., Wimberger J., He Y. Quantification of HDL particle concentration by calibrated ion mobility analysis. Clin Chem 2014, 60(11):1393-1401.
35. Huang R., Silva R.A., Jerome W.G., Kontush A., Chapman M.J., Curtiss L.K., et al. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 2011, 18:416-422.
36. Kontush AC M.J. High-Density Lipoproteins: Structure, Metabolism, Function and Therapeutics 2012, Wiley & Sons, New York.
37. Davidson W.S. HDL-C vs HDL-P: How changing one letter could make a difference in understanding the role of high-density lipoprotein in disease. Clin Chem 2014, 60(11):e1-e3.
38. von Beckerath N., Taubert D., Pogatsa-Murray G., Schomig E., Kastrati A., Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the isar-choice (intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect) trial. Circulation 2005, 112:2946-2950.